Collagenex Pharmaceuticals Inactive 10-Q2006 Q1 Quarterly report

Filed: 8 May 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: accelerated, acceleration, anniversary, annum, Aprecin, assuming, attaining, attractive, authoritative, awarded, basic, began, binding, Brook, capsule, check, chemical, Constant, criteria, debt, decentralized, deleted, deposit, dermal, difficult, diluted, dilution, distinct, domestic, eleven, Employer, enjoyed, erythema, existing, exit, factor, February, federal, filer, forecast, forfeiture, FSP, function, furnish, grew, Healthcare, institutional, issuer, judicial, lack, larger, largest, life, line, MAA, margin, mark, member, met, MHRA, NDA, NIH, nonqualified, par, paragraph, permanent, perpetual, placement, pool, preceding, procedure, prospective, PTS, quickly, redeemed, referenced, relinquish, restate, restated, retrospective, roll, rolled, rolling, SAB, saleable, SansRosa, secondary, shell, shorter, skin, source, Stony, subsequent, surrendered, thereof, timetable, tranche, transferred, Treasury, unissued, Unorthodoxy, unused, unvested, valuable, warehousing, yield, Zedara

Removed: abnormal, accrual, amendment, applying, ARB, attributable, capacity, cGMP, Chapter, choice, clarify, comprehensive, consideration, conversion, core, criterion, dedicated, deducted, detailing, determinable, determining, double, fixed, freight, guidance, handling, idle, incentivize, liquidated, measured, measurement, note, organization, pediatric, periodontal, record, recover, regulation, rehandling, resulted, spoilage, varied, wasted, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Collagenex Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of CollaGenex Pharmaceuticals, Inc. (the “Company”) for the period ended March 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Colin W. Stewart, Chief Executive Officer of the Company, and Nancy C. Broadbent, Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: May 8, 2006		/s/ Colin W. Stewart
		Colin W. Stewart
		Chief Executive Officer


Dated: May 8, 2006		/s/ Nancy C. Broadbent
		Nancy C. Broadbent
		Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.